






Design and Analysis Strategies for Embedded Pragmatic Clinical Trials

ASN Kidney Week
November 2019

Qilu Yu, PHD

Office of Clinical and Regulatory Affairs, NCCIH, NIH



Outlines

- Design of Pragmatic Clinical Trials
 - Study designs and randomization schemes
 - Endpoints and outcomes
 - Controls
- Data Analysis Considerations
 - Clustering
 - Preferred analytic models
 - Missing data



Methods for pragmatic trials

- Pragmatic trials do not require a completely different set of research designs, measures, analytic methods, etc.
- As always, the choice of methods depends on the research question.
- The research question dictates
 - the intervention, target population, and variables of interest,
 - which dictate the setting, research design, measures, and analytic methods.
- Randomized trials will provide the strongest evidence.
 - What kind of randomized trial depends on the research question and how the intervention will be delivered.



Design of Pragmatic Clinical Trials

Randomization Schemes

- **Individual-randomized trial**

- Individuals randomized to study conditions, no interaction among participants after randomization
- Most drug trials

- **Individually randomized group-treated (IRGT) trial**

- The unit of randomization is the individual, but interventions are delivered in a group setting.
- Many surgical trials
- Many behavioral trials

- **Partially nested randomized trial**

- Unbalanced design with clustering in only one study arm
- **Example:** Participants in one arm receive a group meditation intervention, while those in the other arm receive individualized usual care



Design of Pragmatic Clinical Trials

Randomization Schemes

- **Group-randomized trial (GRT)**

- The unit of randomization is a group or cluster, interaction among members of the same group before and after randomization, and measurement of outcomes is obtained among members of the groups or clusters
- Parallel GRT
Separate but parallel intervention and control conditions throughout the trial, with no crossover
- Stepped Wedge GRT



Design of Pragmatic Clinical Trials

Parallel GRT Designs

- **Group-randomized trial (GRT)**

- Single factor and factorial designs: intervention vs. control

Some GRTs include stratification factors:

Multi-center GRTs cross Condition with Site.

Single-center GRTs often stratify on factors related to the outcome or to the ease of implementation of the intervention.

- Time as a factor

Post-test only; Pre/post-test;

Additional discrete time intervals before and/or after intervention;

Continuous surveillance



Design of Pragmatic Clinical Trials

Parallel GRT Designs

- **Group-randomized trial (GRT)**

- Examples:

ICD-Pieces (Parkland Intelligent e-Coordination and Evaluation System)

TiME (Time to Reduce Mortality in End-Stage Renal Disease)

HiLo (Higher vs. Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis)



TiME

HiLo

A Pragmatic Trial Sponsored by the
National Institutes of Health

Design of Pragmatic Clinical Trials

Group-Randomized Trial

- **Balance across groups**

- *A priori* matching and stratification
 - Either can be used if the investigators want to ensure balance on a potential source of bias.
 - *A priori* stratification is preferred if the investigators expect the intervention effect to be different across strata.
 - *A priori* matching is useful if the matching factors are well correlated with the primary endpoint.
 - Stratification or matching are difficult if there are multiple factors and a limited number of groups to be randomized.
- Constrained randomization
 - Generate all possible allocations.
 - Identify those that are sufficiently well balanced across conditions on key covariates.
 - Choose one allocation at random to use for the trial.



Design of Pragmatic Clinical Trials

Stepped-Wedge Group-Randomized Trial

- Key methodological considerations
 - Confounding by time
 - Due to staggered implementation, time is correlated with intervention
 - Secular trend.
 - Contamination
 - Increased risk of within-group contamination: groups may implement intervention earlier or later than planned.
 - Time-varying intervention effects
 - Effects of intervention may vary depending on calendar time, or time since the intervention was introduced
 - Effect heterogeneity
 - Treatment effect may vary across groups, due to variation in quality of implementation, fidelity etc.
 - Complex correlations
 - Repeated measures on same group, and possibly same participants.



Design of Pragmatic Clinical Trials

Randomization Schemes

Design	Unit of Randomization	Intervention
Individual-randomized trial	Individual	Individual level
Individually randomized group-treatment trial	Individual	Group level
Partially nested randomized trial	Individual	Group level for one intervention arm; Individual level for the other intervention arm
Group-randomized trial	Group	Group level
Stepped-wedge group-randomized trial	Group	Group level



Design of Pragmatic Clinical Trials


The Need for Different Designs

- An RCT is the best comparative design whenever...
 - Individual randomization is possible without post-randomization interaction.
- An IRGT is the best comparative design whenever...
 - Individual randomization is possible but there are reasons to allow post-randomization interaction.
- A GRT is the best comparative design whenever the investigator wants to evaluate an intervention that...
 - Cannot be delivered to individuals without risk of contamination.
- An SW-GRT is an alternative to a parallel GRT if...
 - It is unethical to withhold the intervention from any groups.
 - It is impossible to implement the intervention in many groups simultaneously.
 - External events are unlikely to affect the outcomes.



Design of Pragmatic Clinical Trials

Choice of Randomization Scheme



^a If the intervention is delivered through a physical or a virtual group, or through shared interventionists who each work with multiple participants, positive ICC can develop over the course of the trial.

^b There may be logistical reasons to randomize groups or it may not be possible to deliver the intervention to individuals without substantial risk of contamination.

^c There may be legitimate political or logistical reasons to roll out the intervention to all groups before the end of the trial.



Design of Pragmatic Clinical Trials

Endpoints and Outcomes

- Pragmatic outcomes:
 - Relevant for patients, physicians and clinical decision making
 - Mortality, morbidity, functional status, well-being and resource use
 - Generalizable, routinely collected outcomes
 - The inclusion of objective outcome measures

- Patient-reported outcomes (PROs):
 - Outcomes that represent subjective experiences, such as pain, symptoms and physical functions
 - Integration of PROs with EHR system
 - Other types of PROs, such as co-morbidities and hospitalizations, may also be obtained from the EHR or claims data



Design of Pragmatic Clinical Trials

Controls

- Active controls
 - Group intervention, such as education control, to provide social interaction with other participants and the practitioner.
 - Individual intervention, such as sham or simulated interventions.
- Waitlist controls
 - A contemporaneous group that has the promise of receiving the active intervention either after study completion or during a later follow-up period of the study
- Usual care
 - Variations among usual care
 - Potential drift in usual care over time



Data Analysis Considerations

■ Clustering

Clustering introduced by group-treatment in either one or both study arms must be accounted for.

- In the sample size calculations:
Intraclass correlation coefficient (ICC): a measure of how similar the outcomes of individuals within a cluster are likely to be, relative to those of other clusters.
- Account for clustering In statistical analysis

TABLE 1

Relationship between Intraclass Correlation, Sample Size, and Number of Groups

NUMBER OF PHYSICIANS PER TREATMENT ARM	INTRACLASS CORRELATION (RHO)	SAMPLE SIZE (TOTAL)
4	0.0	200
	0.01	396
	0.02	∞
	0.03	∞
10	0.0*	200
	0.01	248
	0.02	320
	0.03	486
20	0.0*	200
	0.01	220
	0.02	246
	0.03	278

*No physician effect.

From "Primer on Group Randomized Trials." *Effective Clinical Practice*, January/February 2001. 1:42-43.



Data Analysis Considerations

- ICC

Scott & Holt (1982) estimate the effect of the ICC as:

$$DEFF = 1 + (m - 1) ICC_y ICC_x$$

- Design effect DEFF is the ratio of the variance as observed to the variance under simple random sampling.
- ICC_y is the ICC for the dependent variable.
- ICC_x is the ICC for the independent variable.

- Sample size $N = \text{effective sample size} \times DEFF$

Scott AJ, Holt D. The effect of two-stage sampling on ordinary least squares methods. *Journal of the American Statistical Association*. 1982;77(380):848-54.



Data Analysis Considerations

- Preferred analytic models for GRTs with 1 or 2 time intervals:
 - Mixed-model ANOVA/ANCOVA
 - Extension of the familiar ANOVA/ANCOVA based on the General Linear Model
 - Fit using the General Linear Mixed Model or the Generalized Linear Mixed Model
 - Accommodates regression adjustment for covariates
 - Can not misrepresent over-time correlation
 - Can take several forms
 - Posttest-only ANOVA/ANCOVA
 - ANCOVA of posttest with regression adjustment for pretest
 - Repeated measures ANOVA/ANCOVA for pretest-posttest design



Data Analysis Considerations

- Preferred analytic models for GRTs with 3 or more time intervals:
 - Random coefficients models
 - Also called growth curve models
 - The intervention effect is estimated as the difference in the condition mean trends.
 - Random coefficients models allow for heterogeneity of those trends.



Data Analysis Considerations

- Individually Randomized Group Treatment Trials:
 - Analyses that ignore the ICC risk an inflated Type I error rate (cf. Pals et al., 2008; Baldwin et al., 2011).
 - Not as severe as in a GRT, but can exceed 15% under conditions common to these studies.
 - The solution is the same as in a GRT.
 - Analyze to reflect the variation attributable to the groups defined by the patterns of interaction.
 - Base df on the number of groups, not the number of members.
 - Mixed models are the most common approach.

Pals SL, Murray DM, et al. Individually randomized group treatment trials: a critical appraisal of frequently used design and analytic approaches. *Am J Public Health*. 2008;98(8):1418-24. PMID18556603.

Baldwin SA, Bauer DJ, et al. Evaluating models for partially clustered designs. *Psych Methods*. 2011;16(2):149-65. PMID21517179.



Data Analysis Considerations

- **Missing Data**

- Missing items or questionnaires in PROs such as measures for pain, physical function and quality of life
- Loss to follow-up in trials with outcomes measured repeatedly over time
- Inability or unwillingness of participants to meet appointments for evaluation
- Missing data due to the lack of Medicare Advantage plan data being released with CMS claims
- Impact on sample size/power
- Assessment of the extent and nature of missingness
- Missing data techniques



Resources of Information

- NIH Collaboratory
Rethinking Clinical Trials®: A Living Textbook of Pragmatic Clinical Trials
<https://rethinkingclinicaltrials.org/>
- Pragmatic and Group-Randomized Trials in Public Health and Medicine
<https://prevention.nih.gov/grt>
- Mind the Gap Webinars
<https://prevention.nih.gov/education-training/methods-mind-gap>
- Research Methods Resources Website
<https://researchmethodsresources.nih.gov/>





Contact

1-888-644-6226
info@nccih.nih.gov

nccih.nih.gov

Connect



nccih.nih.gov/connect

